Becton Dickinson BDX Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Mon, February 9, 2026 astatine 8:41 AM CST 44 min read

Image source: The Motley Fool.

Feb. 9, 2026, 8 a.m. ET

• Chairman, Chief Executive Officer, and President — Tom Polen

• Senior Vice President and Interim Chief Financial Officer — Vitor Roach

Tom Polen, Becton, Dickinson and Company's Chairman, Chief Executive Officer and President, and Victor Roach, Senior Vice President and Interim Chief Financial Officer. Before we get started, I privation to punctual you that we volition beryllium making forward-looking statements. You tin work the disclaimer successful our net merchandise and the disclosures successful our SEC filings connected our Investor Relations website. Unless different specified, each comparisons volition beryllium made connected a year-on-year ground versus the applicable fiscal period. Revenue percent changes are connected an FX-neutral ground unless different noted. Also, references to adjusted EPS notation to adjusted diluted EPS.

As a reminder, opening October 1, we began operating nether our antecedently disclosed caller Becton, Dickinson and Company conception operation that includes Medical Essentials, Connected Care, Biopharma Systems, and Interventional, and a 5th Life Sciences conception comprised of Biosciences Diagnostic Solutions. The financials discussed present and included successful the net merchandise and 10-Q person been recast to bespeak this reorganization. Reconciliations betwixt GAAP and non-GAAP measures are included successful the appendices of the net merchandise and presentation. With that, I volition crook it implicit to Tom.

Tom Polen: Thank you, Sean, and bully morning, everyone. Before we get started, I'd similar to instrumentality a infinitesimal to invited Sean to Becton, Dickinson and Company. We are precise excited to person Sean articulation our team, and I look guardant to partnering with him arsenic we proceed to pass our strategy, performance, and maturation opportunities. Turning to our Q1 performance, we delivered stronger than expected results which bespeak our disciplined execution, including accelerated commercialized initiatives and strengthening our cardinal maturation platforms. Revenues of $5.3 cardinal accrued 0.4%. New Becton, Dickinson and Company grew 2.5%, with broad-based maturation crossed the markets wherever we've been doubling down connected investments.

This includes double-digit maturation successful biologic cause delivery, PIRWIC, precocious insubstantial regeneration, Pharmacy Automation, and precocious single-digit maturation successful APM. We delivered mid-single-digit maturation crossed 90% of New Becton, Dickinson and Company's portfolio. Partially offset by 10% of our portfolio Alaris vaccines successful China undergoing challenging marketplace dynamics that were successful enactment with our expectations. We delivered an adjusted gross borderline of 53.4%, and adjusted EPS of $2.91 some of which were besides up of our expectations connected the spot of gross show and operational execution. Later this morning, we expect to adjacent the operation of our beingness sciences concern with Waters via a Reverse Morris Trust transaction.